Brian Mendelsohn
Executive Director, ADCs Exelixis, Inc.
Seminars
Tuesday 4th November 2025
Presentation Sneak Peek:
Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC
- XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
- Laying out demonstration of in vitro bystander and ICD activity
- Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
Tuesday 4th November 2025
Presentation Sneak Peek:
Exploring Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC
- XB371 is designed as a novel belotecan ADC, created with the SMARTag ADC platform
- Laying out demonstration of in vitro bystander and ICD activity
- Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models
